title: Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study.
authors.forename: A S
authors.initials: AS
authors.lastname: Wierzbicki
authors.forename: S
authors.initials: S
authors.lastname: Pendleton
authors.forename: Z
authors.initials: Z
authors.lastname: McMahon
authors.forename: A
authors.initials: A
authors.lastname: Dar
authors.forename: J
authors.initials: J
authors.lastname: Oben
authors.forename: M A
authors.initials: MA
authors.lastname: Crook
authors.forename: A J
authors.initials: AJ
authors.lastname: Botha
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors*; D002784:Cholesterol / Q000378:metabolism*; D005234:Fatty Liver / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D009767:Obesity, Morbid / Q000188:drug therapy* / Q000378:metabolism; D010880:Piperidines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077285:Rimonabant; D056737:Safety-Based Drug Withdrawals; D014280:Triglycerides / Q000378:metabolism; D015431:Weight Loss / Q000187:drug effects
chemical_list: D015415:Biomarkers; D063385:Cannabinoid Receptor Modulators; D010880:Piperidines; D011720:Pyrazoles; D014280:Triglycerides; D002784:Cholesterol; D000077285:Rimonabant